autologous anti-cd19car-4-1bb-cd3zeta-egfrt-expressing t lymphocytes
Cell therapyexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2013 (NCT01865617)
Timeline
2010s
- Jan 1, 2013
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
- Antigens, CD19 · Phase 1/Phase 2
- Leukemia, Lymphocytic, Chronic, B-Cell · Phase 1/Phase 2
- Lymphoma · Phase 1
- Lymphoma, B-Cell · Phase 1
- Lymphoma, Large B-Cell, Diffuse · Phase 1/Phase 2
- Lymphoma, Large-Cell, Immunoblastic · Phase 1
- Lymphoma, Mantle-Cell · Phase 1/Phase 2
- Lymphoma, Non-Hodgkin · Phase 1/Phase 2
- Lymphoma, Primary Cutaneous Anaplastic Large Cell · Phase 1/Phase 2
- Precursor B-Cell Lymphoblastic Leukemia-Lymphoma · Phase 1/Phase 2
Mechanism of action
- Tumor antigensImmunity, passive
immunity, passive - tumor antigens
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- autologous anti-cd19car-4-1bb-cd3zeta-egfrt-expressing t lymphocytes
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03103971 | Phase 1 | Jul 17, 2017 | National Cancer Institute (NCI), University of Washington |
| NCT01865617 | Phase 1/Phase 2 (Phase 2) | May 1, 2013 | National Cancer Institute (NCI), University of Washington |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 2 | 0 | 2 | 2013 |
| University of Washington | Academic/Hospital | 2 | 2 | 2 | 2013 |
2 organizations
Page 1 / 1